Interaction Checker
Potential Interaction
Dolutegravir/Lamivudine (DTG/3TC)
Carbamazepine
Quality of Evidence: Very Low
Summary:
Coadministration with Dovato (dolutegravir/lamivudine) has not been studied. No significant interaction is expected with lamivudine. However, the dolutegravir dose (50 mg) in Dovato is insufficient when coadministered with certain drugs (such as carbamazepine) that may decrease dolutegravir concentrations. Coadministration of carbamazepine (300 mg twice daily) and dolutegravir alone (50 mg once daily) decreased dolutegravir Cmax, AUC and Cmin by 33%, 49% and 73%, respectively. The European and US product labels for Dovato recommend that an additional 50 mg tablet of dolutegravir, separated by 12 hours from Dovato, should be taken. This dose adjustment should be maintained for approximately 2 weeks after stopping carbamazepine as the inducing effect may persist after discontinuation of a strong inducer. Considering the limited experience when coadministering inducers with dual antiretroviral regimens, close monitoring of HIV infection is recommended. Limited data from a small number of patients showed TDM evaluations for carbamazepine and oxcarbazepine were within the therapeutic ranges and trough concentrations for dolutegravir were ~83% lower when compared with HIV-infected patients not treated with antiepileptic drugs. A case report describes a person living with HIV on dolutegravir/lamivudine/tenofovir-DF (50/300/245 mg once daily) and carbamazepine (400 mg once daily) who remained virologically suppressed. The extrapolated dolutegravir concentration 24 h post-dose was estimated to be 670 ng/mL (clinical target concentration 300 ng/mL). The magnitude of the interaction with carbamazepine in this patient was less pronounced than in a published drug interaction study and is likely due to the lower dose of carbamazepine in this patient (400 mg) compared to the dose used in the interaction study (600 mg) given that carbamazepine induction is dose/concentration dependent.
Description:
View all available interactions with Dolutegravir/Lamivudine (DTG/3TC) by clicking here.
Copyright © 2026 The University of Liverpool. All rights reserved.